EQUILLIUM, INC. Interest Payable, Current
EQUILLIUM, INC. (EQ) had Interest Payable, Current of $66.00 thousand as of 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Accrued Liabilities, Current
us-gaap:InterestPayableCurrent · last filed 2024-03-25
- 2023-03-31: Interest Payable, Current $66.00K.
- 2022-12-31: Interest Payable, Current $74.00K.
- 2022-09-30: Interest Payable, Current $71.00K.
- 2022-06-30: Interest Payable, Current $69.00K.
| Period end | Interest Payable, Current |
|---|---|
| 2023-03-31 | $66.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $74.00K 10-K · filed 2024-03-25 |
| 2022-09-30 | $71.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $69.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $71.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $71.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $69.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $69.00K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $71.00K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $71.00K 10-K · filed 2022-03-23 |
| 2020-09-30 | $69.00K 10-Q · filed 2020-11-10 |
| 2020-06-30 | $69.00K 10-Q · filed 2020-08-12 |
| 2020-03-31 | $71.00K 10-Q · filed 2020-05-13 |
| 2019-12-31 | $71.00K 10-K · filed 2021-03-24 |
| 2018-09-30 | $478.82K 10-Q · filed 2018-11-15 |
| 2017-12-31 | $88.37K 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |